Verrica Pharmaceuticals Inc. (VRCA )

Currency in USD Disclaimer
$5.69 +$0.62 (12.23%)
Closed 08/28/2026
$5.01
$5.85
$3.28
$9.82

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol VRCA
  • Company Verrica Pharmaceuticals Inc.
  • Price $5.69
  • Changes Percentage 12.23
  • Change 0.62
  • Day Low $5.01
  • Day High $5.85
  • Year High $9.82
  • Year Low $3.28
  • Market Cap $82,801,744
  • Price Avg 50 EMA (D) $5.6
  • Price Avg 200 EMA (D) $6.18
  • Exchange NASDAQ
  • Volume 78,811
  • Average Volume 46,320
  • Open $5.12
  • Previous Close $5.07
  • EPS -0.82
  • PE -5.88
  • Earnings Announcement 2026-11-13 05:00:00
  • Shares Outstanding $17,178,785

Company brief: VERRICA PHARMACEUTICALS INC. (VRCA )

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

VRCA Corporation News

Income Statement